Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects
Yueyao Jiang,Chengran Wang,Chuancheng Zu,Xin'ao Rong,Qian Yu,Jinlan Jiang
DOI: https://doi.org/10.2147/ijn.s466396
IF: 7.033
2024-10-02
International Journal of Nanomedicine
Abstract:Yueyao Jiang, 1, * Chengran Wang, 2, * Chuancheng Zu, 3, * Xin'ao Rong, 2 Qian Yu, 1 Jinlan Jiang 2 1 Department of Pharmacy, China–Japan Union Hospital of Jilin University, Changchun, Jilin Province, 130033, People's Republic of China; 2 Department of Scientific Research Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin Province, 130033, People's Republic of China; 3 China–Japan Union Hospital of Jilin University, Changchun, Jilin Province, 130033, People's Republic of China *These authors contributed equally to this work Correspondence: Qian Yu, Department of Pharmacy, China–Japan Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, Jilin Province, 130033, People's Republic of China, Email Jinlan Jiang, Department of Scientific Research Center, China–Japan Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun, Jilin Province, 130033, People's Republic of China, Email Given the global prevalence of prostate cancer in men, it is crucial to explore more effective treatment strategies. Recently, immunotherapy has emerged as a promising cancer treatment due to its unique mechanism of action and potential long-term effectiveness. However, its limited efficacy in prostate cancer has prompted renewed interest in developing strategies to improve immunotherapy outcomes. Nanomedicine offers a novel perspective on cancer treatment with its unique size effects and surface properties. By employing targeted delivery, controlled release, and enhanced immunogenicity, nanoparticles can be synergized with nanomedicine platforms to amplify the effectiveness of immunotherapy in treating prostate cancer. Simultaneously, nanotechnology can address the limitations of immunotherapy and the challenges of immune escape and tumor microenvironment regulation. Additionally, the synergistic effects of combining nanomedicine with other therapies offer promising clinical outcomes. Innovative applications of nanomedicine include smart nanocarriers, stimulus-responsive systems, and precision medicine approaches to overcome translational obstacles in prostate cancer immunotherapy. This review highlights the transformative potential of nanomedicine in enhancing prostate cancer immunotherapy and emphasizes the need for interdisciplinary collaboration to drive research and clinical applications forward. Keywords: prostate cancer, nanomedicine, immunotherapy, TME Graphical Prostate cancer is the second most common malignancy in men worldwide and is a leading cause of death among males. 1 Androgen deprivation therapy (ADT) is the main treatment for advanced prostate cancer. However, most patients who receive ADT ultimately progress to castration-resistant prostate cancer (CRPC), with a median survival of less than two years. 2 Recent advancements in treatment have moderately improved survival rates for CRPC patients. However, the overall prognosis remains poor, and advanced prostate cancer is currently untreatable. 3,4 Hence, advanced treatment strategies are required to improve patient survival and prognosis. The development of cancer immunotherapy has represented a significant milestone in oncology. 5,6 Immunotherapy, encompassing immune checkpoint inhibitors, antibody–drug conjugates (ADCs), cell therapy, and vaccine therapy, activate or regulate the immune system to eliminate cancer cells and achieve therapeutic effects. 7,8 The 2018 Nobel Prize in Physiology or Medicine was awarded for groundbreaking research on immune checkpoint molecules, specifically cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1), which have significantly advanced the field of immunotherapy. 9 Although immunotherapy has become an important tool in prostate cancer treatment, activating the immune system to recognize and destroy cancer cells, it faces several challenges, including immune escape mechanisms that allow cancer cells to evade surveillance and attack by the immune system, immune-related side effects caused by treatment, 10 and inconsistent efficacy among patients. 11 Therefore, an urgent need exists to develop new treatment strategies to improve immunotherapy outcomes. Nanomedicine has shown great potential in this context as the application of nanotechnology in tumor therapy. 12 Indeed, nanotechnology holds immense promise in advancing the treatment, 13,14 prevention, 15,16 monitoring, 17 and management of biological diseases. 18,19 By integrating nano- and drug technologies, nanotechnology facilitates the development of drug delivery systems and enhances immunotherapy effectivenes -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology